Skip Navigation


JAC Advance Access originally published online on March 24, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/5/700    most recent
dkh161v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rockstroh, J. K.
Right arrow Articles by Mauss, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rockstroh, J. K.
Right arrow Articles by Mauss, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 700-702
© 2004 The British Society for Antimicrobial Chemotherapy

Leading Article

Clinical perspective of fusion inhibitors for treatment of HIV

J. K. Rockstroh1,* and S. Mauss2

1 Department of Medicine I, University of Bonn, Bonn; 2 Center for HIV and Hepatogastroenterology, Düsseldorf, Germany

The number of antiretroviral-experienced HIV patients with multiple resistances against the currently available antiretroviral drug classes is increasing substantially. Therapeutic options for this specific group of patients are limited. The fusion inhibitor enfuvirtide represents the first new therapeutic option from a new drug class for this patient population. An optimized background therapy with remaining antiviral activity appears essential in order to avoid resistance development against enfuvirtide. Despite the high price of enfuvirtide, cost-effectiveness and increase in quality of life have been demonstrated in patients achieving virological control under optimized background and enfuvirtide therapy. In this article, the characteristics and clinical perspectives of fusion inhibitors are presented and discussed.

Keywords: antiretroviral therapy, enfuvirtide, HAART, salvage therapy

* Correspondence address. Medizinische Universitätsklinik I, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. Tel: +49-228-287-6558; Fax: +49-228-287-5034; E-mail: rockstroh{at}uni-bonn.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.